Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Olaparib

Review the clinical trials studying olaparib on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-50 of 57

Olaparib and Durvalumab with Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial
Status: Active
Location: 2 locations
Cirtuvivint and Olaparib for the Treatment of Patients with BRCA/HRD Platinum Resistant Ovarian Cancer
Status: Active
Location: 2 locations
A Microdevice for Candidate Drug Screening in Patients with Skin Squamous Cell Carcinoma
Status: Active
Location: 2 locations
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Olaparib for the Treatment of Homologous Recombination Deficient Malignant Mesothelioma
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Olaparib for Treatment of Metastatic Kidney Cancer in Patients with DNA Repair Gene Mutations, the ORCHID Study
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Olaparib in Combination with Pembrolizumab for the Treatment of Metastatic Uveal Melanoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Olaparib with Ceralasertib for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Carboplatin, Paclitaxel, and Pembrolizumab Before Surgery Followed by Olaparib and Pembrolizumab with or without Bevacizumab for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients with Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Olaparib and Estradiol for the Treatment of Metastatic or Locally Recurrent ER+/HER2- Breast Cancer, PHOEBE Trial
Status: Active
Location: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire
Adagrasib in Combination with Olaparib for the Treatment of KRAS G12C Mutated Advanced Solid Tumors with a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Telmisartan Alone or Combined with Selected Standard of Care Therapy for the Treatment of Prostate Cancer
Status: Active
Location: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Status: Active
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation
Status: Active
Location: See ClinicalTrials.gov
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Status: Enrolling by Invitation
Location: Asplundh Cancer Pavilion, Willow Grove, Pennsylvania
Evaluation of Circulating Tumor DNA Levels as a Predictive Marker for Switching Treatment Earlier in Patients with Metastatic Breast Cancer
Status: Temporarily Closed to Accrual
Location: 8 locations
Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients with Pancreatic Cancer That Has Spread with Inherited BRCA Mutations
Status: Temporarily Closed to Accrual
Location: 2 locations
Olaparib with LHRH Agonist Followed by Radical Prostatectomy in the Treatment of Unfavorable Intermediate or High Risk Prostate Cancer with BRCA1/2 Gene Alterations
Status: Temporarily Closed to Accrual
Location: 5 locations
Olaparib, Cabazitaxel, Carboplatin, and Prednisone in Treating Patients with Metastatic Prostate Cancer
Status: Temporarily Closed to Accrual
Location: 2 locations
Selumetinib and Olaparib in Treating Participants with Relapsed or Refractory and Advanced Endometrial, Ovarian, or Other Solid Tumors with RAS Pathway Alterations
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas